Ventoux Biosciences

Ventoux Biosciences is advancing VEN-201, a potential disease-modifying therapy for Dupuytren's disease, a progressive hand condition affecting over 6 million Americans. Ventoux is developing a patented, versatile treatment to slow early disease progression and reduce recurrence after procedures. Our immunofibrotic modulator demonstrates promising preclinical efficacy and aims to transform care in a $4.3B market currently limited to acute treatments.